Prevention & care

Multiple endocrine neoplasia type 2: RET inheritance, MEN2A and MEN2B, medullary thyroid cancer, prevention, and targeted treatment

12 sources · Latest source check 2026-10-09 UTC

On this page

Multiple endocrine neoplasia type 2 (MEN2) is a RET-related inherited tumor-predisposition syndrome. Medullary thyroid cancer is central; adrenal pheochromocytomas and parathyroid disease have phenotype-specific relevance. A genetic risk result and an existing cancer’s stage are different findings.[1]

Phenotype labels describe characteristic patterns

Phenotype labels describe characteristic patterns
Label	Broad pattern
MEN2A	Medullary thyroid cancer, pheochromocytoma and parathyroid adenoma/hyperplasia risks.[2]
MEN2B	Medullary thyroid cancer and pheochromocytoma; mucosal neuromas and gastrointestinal nerve changes can occur.[2]
Familial medullary thyroid cancer	A historically separate label for families dominated by medullary cancer; current NCI classification places it within MEN2A.[1]

RET encodes a signaling protein

MedlinePlus describes RET as a cell-signaling gene. MEN2-related activating variants can produce excessive signaling that promotes abnormal cell growth. Other RET variants have different effects, including impaired signaling in some Hirschsprung disease settings. A gene name alone is therefore insufficient; the specific variant and clinical interpretation matter.[3]

No recognized family history does not exclude inherited susceptibility

MEN2 generally follows autosomal dominant inheritance, and some cases arise from new variants. Relatives may benefit from assessment when a familial pathogenic variant is identified. Testing should distinguish a confirmed disease-associated change from an unexplained finding; a consumer report is not a substitute for clinical genetic interpretation.[4]

Tumor RET testing and inherited-risk testing serve different purposes

MedlinePlus describes somatic RET alterations in sporadic cancers. These are acquired in selected cells rather than inherited throughout the body. A RET-positive tumor can therefore qualify for a tumor-directed medicine without, by itself, confirming MEN2. Testing a tumor and assessing relatives are related but distinct clinical tasks.[3]

Familial medullary thyroid cancer appears under different headings

GeneReviews lists MEN2A, MEN2B and familial medullary thyroid carcinoma as included phenotypes. The NCI’s detailed PDQ places the familial-medullary label within MEN2A and emphasizes genotype alongside phenotype. These are classification differences, not three successive stages. A family label should not replace a variant-specific assessment of other endocrine risks.[1]

Brief glossary entries can flatten clinically relevant distinctions

An NCI dictionary entry broadly groups tumor risks across all subtypes. Its detailed PDQ and GeneReviews instead distinguish phenotype-specific patterns, including parathyroid adenoma/hyperplasia in MEN2A. This article follows those detailed distinctions rather than treating every listed gland risk as identical in every phenotype.[5][2]

Medullary cancer arises from a different thyroid cell population

The ATA describes medullary thyroid cancer as arising from C cells, which produce calcitonin. Most common differentiated thyroid cancers arise from follicular cells that make thyroid hormone. Consequently, a normal TSH result can coexist with medullary cancer; thyroid hormone function and a tumor-marker question are different measurements.[6]

A marker is interpreted alongside the actual disease context

The ATA describes calcitonin and carcinoembryonic antigen (CEA) in evaluation and follow-up, together with tissue diagnosis and imaging when indicated. A marker result does not supply the complete stage or operative plan. Trends, assay interpretation and the clinical setting matter rather than an isolated internet cutoff.[6]

Germline testing can change care before symptoms develop

ATA guidance addresses germline RET assessment even in apparently sporadic medullary thyroid cancer, because inherited disease may not be obvious. Identifying a pathogenic familial variant helps organize counseling and assessment of relatives. Testing is intended to clarify care, not to assume every carrier already has the same tumors.[7]

Preventive thyroidectomy is distinct from treating already advanced cancer

The guideline’s hereditary-risk categories depend on interpreted RET variants and expected aggressiveness. Surgery timing requires specialist assessment, especially for very early-risk MEN2B. Removing thyroid tissue also creates replacement and monitoring needs. An old guideline table cannot be safely converted into a self-selected operation date without contemporary clinical review.[7]

Pheochromocytoma changes preparation for surgery

GeneReviews describes assessment for functioning pheochromocytoma before surgery, including plasma or urine metanephrines. When pheochromocytoma is identified, its management precedes thyroid surgery to avoid a catecholamine crisis. This is a specialist sequence of care, not a reason to stop medicines or order unsupervised screening without context.[2]

A large retrospective study supports early recognition but has causal limits

A 2019 international study used records from forty-eight centers and included 345 people with the M918T RET variant. Only twenty underwent thyroidectomy before age one. Remission was reported in 15/18 evaluable early-operation patients versus 47/318 later-operation patients. These selected historical groups were not randomized.[8]

The survival comparison was imprecise and not statistically conclusive; it should not be relabeled as a precisely measured survival benefit. Differences in presentation, timing and decades of care affect interpretation. The abstract lists no funding, while original article acknowledgments note NCI institutional support. The study supports awareness, not a personal prognosis.[8]

Treatment cannot simply be copied from another thyroid cancer type

ATA patient information explains that radioactive iodine is not a treatment for medullary cancer because its cells do not take up iodine as follicular cells do. Surgery, surveillance and selected systemic treatment have different roles. The phrase “thyroid cancer” alone does not select one common treatment pathway.[6]

Selpercatinib has a defined advanced-cancer indication

FDA granted traditional approval in September 2024 for selpercatinib in adults and children aged two or older with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy. That indication is not routine preventive drug treatment for every MEN2 carrier. Regulatory summaries and publications may share the same underlying trial.[9]

An effective targeted drug still needs product-specific monitoring

The retrieved Retevmo label was updated September 11, 2026, with major indication and warning revisions dated July 2026. It includes liver injury, lung inflammation, hypertension, QT prolongation, bleeding, wound-healing and other precautions. Drug interactions and monitoring belong in a prescriber-led plan; efficacy does not mean unrestricted use.[12]

Its indications separately distinguish a RET mutation in medullary cancer from RET fusions in other cancers. A fusion, an activating inherited variant and an uncertain genetic result should not be treated as interchangeable. The specific tumor, specimen, age and clinical need matter for eligibility.[12]

Evidence & uncertainty

Genetic assessment, specialist surveillance and risk-adapted thyroid surgery have established guidance. Timing and lifetime outcomes are not answered by one uniform schedule. Trials of drugs for advanced cancer answer a separate question from preventing cancer in an unaffected RET-variant carrier. Current labels also qualify older treatment descriptions.[1][9]

Selected-source overview · Independent review pending

Published questions

Are MEN2A, MEN2B and familial medullary thyroid cancer successive stages?

Selected-source overview · Independent review pending. Read the evidence context.

They are phenotype/classification labels; familial-medullary terminology differs across references.[1]

Evidence behind this answer

Multiple Endocrine Neoplasia Type 2 (MEN2) (PDQ): health professional version
agency condition or prevention explanation · Date not stated
Original indexed selected PDQ clinical/classification passages inspected · RET-related syndrome, phenotype/genotype classification and evolving thyroidectomy decisions